MedTrace Logo

Conventional Versus Hypofractionated Radiation in High Risk Prostate Patients

NCT01488968 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 111

Last updated 2025-06-29

No results posted yet for this study

Summary

Hypofractionated regimen in high-risk prostate cancer will allow the investigators to deliver higher biological doses to targets in order to improve tumor control and with acceptable rectal toxicity compared to conventional fractionation.

Conditions

  • High-risk Prostate Cancer

Interventions

RADIATION

Standard Radiation Treatment

39 radiation treatments

RADIATION

Hypofractionated radiation treatment

25 radiation treatments

Sponsors & Collaborators

  • AHS Cancer Control Alberta

    lead OTHER

Principal Investigators

  • Albert Murtha · Cross Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2018-10-15
Completion
2018-10-15

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01488968 on ClinicalTrials.gov